Clinical Trials

Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT05372640 2026-04-13

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

45 enrolled

Phase 2 Active not recruiting

Breast Neoplasms, Neoplasm Metastasis

NCT05554341 2026-04-13

Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial

40 enrolled

Neoplasm Metastasis

NCT05554380 2026-04-13

Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial

Phase 2 Suspended

33 enrolled

Neoplasm Metastasis

NCT05687110 2026-04-13

Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes

43 enrolled

Neoplasm Metastasis

NCT05687136 2026-04-13

Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors

66 enrolled

Neoplasm Metastasis

NCT05691491 2026-04-13

Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness

Phase 1/2 Recruiting

58 enrolled

Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms

NCT05691517 2026-04-13

Testing How the Body Responds to the Drug CBX-12 in Patients With Advanced Solid Cancers

35 enrolled

Neoplasm Metastasis

NCT05803382 2026-04-13

Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers

30 enrolled

Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms

NCT06223542 2026-04-13

Studying TAK-243 in Patients With Advanced Cancer

95 enrolled

Neoplasm Metastasis

NCT06311214 2026-04-13

Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

Phase 2 Recruiting

500 enrolled

Neoplasm Metastasis

NCT06364410 2026-04-13

Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors

48 enrolled

Gastrointestinal

Neoplasm Metastasis, Stomach Neoplasms

NCT06606990 2026-04-13

Testing How the Body Responds to the Drug CX-5461 (Pidnarulex) in Patients With Metastatic Solid Cancers

40 enrolled

Neoplasm Metastasis

NCT07137416 2026-04-13

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

36 enrolled

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT04119024 2026-03-17

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

BreastCNSDermatologicEndocrineHead & NeckNETThoracic

18 enrolled

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Uveal Melanoma, Breast Neoplasms, Adenoma, Islet Cell, Melanoma, Neoplasm Metastasis, Paraganglioma, Pheochromocytoma, Thyroid Neoplasms, Adrenocortical Carcinoma, Neuroendocrine Tumors

NCT07477457 2026-03-17

A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma

Phase 2 Recruiting

45 enrolled

Sarcoma

Neoplasm Metastasis, Osteosarcoma

NCT05098210 2026-03-12

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

25 enrolled

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Neoplasm Metastasis

NCT05269381 2026-03-12

PNeoVCA

Phase 1/2 Recruiting

132 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinosarcoma, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04294628 2026-02-27

Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer

62 enrolled

GastrointestinalSarcomaThoracic

Neoplasm Metastasis

NCT02408861 2026-01-21

Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Phase 1 Terminated

79 enrolled 24 charts

Anus Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Sarcoma, Kaposi, HIV Infections

NCT04673448 2026-01-09

Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer

BreastGastrointestinalGynecologic

18 enrolled

Breast Neoplasms, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms

NCT06320405 2025-12-29

Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors

Phase 1/2 Recruiting

38 enrolled

DermatologicGastrointestinalGenitourinaryGynecologic

Neoplasm Metastasis

NCT06626256 2025-12-24

STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma

Phase 1 Withdrawn

Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms

NCT06043713 2025-12-19

Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Solid Tumor Cancers With KRAS G12V Mutations

24 enrolled

Neoplasm Metastasis

NCT04329494 2025-12-10

PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer

GastrointestinalGynecologic

49 enrolled

Appendiceal Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Peritoneal Neoplasms, Stomach Neoplasms, Uterine Neoplasms, Colorectal Neoplasms

NCT05035407 2025-12-02

T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers

Phase 1 Terminated

36 enrolled 7 charts

Carcinoma, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT03842228 2025-10-14

COD

39 enrolled 15 charts

Phase 1/2 Active not recruiting

Neoplasm Metastasis

NCT02079740 2025-09-30

Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors

96 enrolled 30 charts

Neoplasm Metastasis

NCT06942104 2025-07-18

Imaging of Solid Tumors Using 18F-TRX

56 enrolled

CNSGenitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell, Glioma, Neoplasm Metastasis, Prostatic Neoplasms

NCT04514497 2025-03-06

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer

EndocrineGastrointestinalThoracic

28 enrolled

Lung Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

NCT01902173 2025-01-14

Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer

Phase 1/2 Completed

27 enrolled 16 charts

DermatologicOther hematologic neoplasm

Melanoma, Neoplasm Metastasis, Hematologic Neoplasms

NCT05653661 2025-01-07

Nab-Paclitaxel/STI-3031 Complex (AP160-Complex) for the Treatment of Advanced or Metastatic Solid Tumors

Phase 1 Withdrawn

DermatologicGastrointestinalLymphoidSarcomaThoracic

Neoplasm Metastasis

NCT02595866 2024-08-09

Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer

Phase 1 Completed

58 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Non-Hodgkin, Melanoma, Neoplasm Metastasis, Neoplasms, Recurrence, Sarcoma, Kaposi, HIV Infections

NCT03333655 2022-08-12

Study to Explore the Mechanism of Acquired Immune Escape In Participants With Metastatic Cancer Progressing on CPI Therapy

Phase 4 Completed

15 enrolled